Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd Ads (NQ: BGNE )

356.99 USD -5.81 (-1.60%)
Official Closing Price Updated: 4:04 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 234,439
Open 362.70
Bid (Size) 345.00 (1)
Ask (Size) 359.99 (1)
Prev. Close 362.80
Today's Range 349.62 - 362.89
52wk Range 118.55 - 371.37
Shares Outstanding 53,760,296
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer
BeiGene's anti-PD-1 antibody received approval in China in first-line advanced squamous non-small cell lung cancer. 
From Business Wire News Releases
First Week of March 19th Options Trading For BeiGene (BGNE)
Investors in BeiGene Ltd (BGNE) saw new options begin trading this week, for the March 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BGNE options chain... 
Tags Stocks
From Market News Video

Performance

YTD
+36.77%
+36.77%
1 Month
+36.56%
+36.56%
3 Month
+17.99%
+17.99%
6 Month
+51.33%
+51.33%
1 Year
+110.40%
+110.40%

More News

Read More
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
From Business Wire News Releases
Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology
From Business Wire News Releases
3 Lesser-Known Biotech Stocks that are Surging
Tags Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference
From Business Wire News Releases
Week In Review: BeiGene Signs $2.2 Billion Deal With Novartis For PD-1
Tags Pharma/Biotech Stocks / Equities Healthcare
From Blogs - TalkMarkets
Why BeiGene, T2 Biosystems And Amneal Are Are Moving Today
Tags Market News TTOO Movers
From Benzinga
Beigene Stock Breaks Out To Record High On Cancer Drug OK In China
From Investor's Business Daily
Stocks Showing Improved Relative Strength: Beigene
From Investor's Business Daily
Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis
From Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.